# Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

> **NCT04216355** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 20 (estimated)

## Conditions studied

- MDS-EB

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** CAG Protocol

## Key facts

- **NCT ID:** NCT04216355
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216355, "Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04216355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*